[1]黎永华,陈嫦,李光宇,等.复合乳酸菌联合美沙拉嗪治疗中度活动期溃疡性结肠炎患者的临床效果及其对炎性因子的影响[J].内科,2020,15(01):26-28.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.01.09]
 LI Yonghua,CHEN Chang,LI Guangyu,et al.Clinical effect of compound lactobacillus combined with mesalazine on moderate active ulcerative colitis and its effect on inflammatory factors[J].Internal Medicine of China,2020,15(01):26-28.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.01.09]
点击复制

复合乳酸菌联合美沙拉嗪治疗中度活动期溃疡性结肠炎患者的临床效果及其对炎性因子的影响()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
15卷
期数:
2020年01
页码:
26-28
栏目:
论著
出版日期:
2020-03-31

文章信息/Info

Title:
Clinical effect of compound lactobacillus combined with mesalazine on moderate active ulcerative colitis and its effect on inflammatory factors
文章编号:
1673-7768(2020)01-0026-03
作者:
黎永华1陈嫦1李光宇1庞福梅2彭锡其3
1 广东省罗定市人民医院,罗定市527239;2 分界镇卫生院,罗定市分界镇527239;3 黎少镇中心卫生院,罗定市黎少镇527239
Author(s):
LI Yonghua1 CHEN Chang1 LI Guangyu1 PANG Fumei2 PENG Xiqi3
1 People’s Hospital of Luoding, Luoding 527239; 2 Fenjie Town Medical Center, Fenjie Town, Luoding 527239; 3 Central Hospital of Lishao Town, Lishao Town, Luoding 527239, Guangdong Province, China
关键词:
活动期溃疡性结肠炎复合乳酸菌美沙拉嗪炎性因子
Keywords:
Active ulcerative colitis Compound lactobacillus Mesalazine Inflammatory factor
分类号:
R 574
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2020.01.09
文献标志码:
A
摘要:
目的探讨复合乳酸菌联合美沙拉嗪治疗中度活动期溃疡性结肠炎患者的临床效果以及对炎性因子水平的影响。方法选择2016年2月至2019年2月我院收治的中度活动期溃疡性结肠炎患者84例为研究对象,随机分为对照组和研究组,每组42例。对照组患者单纯给予美沙拉嗪治疗,研究组患者给予复合乳酸菌胶囊及美沙拉嗪治疗,疗程4周。比较两组患者的临床治疗效果;检测比较两组患者治疗前后的炎性因子水平;比较治疗期间两组患者不良反应的发生情况。结果研究组患者的治疗总有效率(92.86%)明显高于对照组(73.81%),差异有统计学意义(P<0.05)。治疗4周后,两组患者血清的白介素-8(IL-8)、超敏C反应蛋白(hs-CRP)水平均显著降低,白介素-4(IL-4)水平显著升高,研究组患者血清的IL-8、hs-CRP水平显著低于对照组,IL-4水平显著高于对照组,差异有统计学意义(P<0.05)。治疗过程中,研究组患者的不良反应发生率(11.9%)低于对照组(7.1%),但差异无统计学意义(P>0.05)。结论复合乳酸菌辅助美沙拉嗪治疗活动期溃疡性结肠炎患者,可显著提高临床治疗效果,改善患者炎性因子水平,治疗安全高,值得推广应用。
Abstract:
ObjectiveTo investigate the clinical effect of compound lactobacillus combined with mesalazine on moderate active ulcerative colitis and its effect on inflammatory factors levels. MethodsA total of 84 patients with moderate active ulcerative colitis admitted to our hospital from February 2016 to February 2019 were selected as the research subjects and randomly divided into control group and study group, with 42 cases in each group. Patients in the control group were simply administered mesalazine and the study group with compound lactobacillus capsules and mesalazine, for four-week treatment courses. The clinical therapeutic effect, pre- and post-treatment inflammatory factors levels, and the prevalence of adverse reactions were compared and detected between the two groups. ResultsThe total effective rate of patients in the study group (92.86%) was significantly higher than that in the control group (73.81%), and the difference was statistically significant (P<0.05). After 4 weeks of treatment, both groups yielded significantly decreased levels of serum interleukin 8 (IL-8) and high-sensitivity C-reactive protein (hs-CRP), whereas increased interleukin 4 (IL-4) level. Patients in the study group obtained lower levels of serum IL-8 and hs-CRP, but higher IL-4 level in comparison with the control group, with statistically significant differences (P<0.05). The incidence of adverse reactions in the study group (11.9%) was lower than that in the control group (7.1%) during the treatment, but the difference was not statistically significant (P>0.05). ConclusionMesalazine assisted by compound lactobacillus on moderate active ulcerative colitis can significantly improve clinical therapeutic effect and inflammatory factors levels of patients, and thus it is highly safe for treatment and worthy of promotion and application.
更新日期/Last Update: 2020-04-07